title: Behavioral, Physiological and Biochemical Hormetic Responses to the Autoxidizable Dye Methylene Blue.
abstract: The goals of this review were to identify methylene blue (MB) as a compound that follows hormetic behavior for a wide range of effects and to address the question of what is unique about MB that could account for its wide applicability and hormetic behavior as a drug. The MB hormetic dose-response relationship is exemplified by an increase in various behavioral, physiological and biochemical responses with increasing dose, followed by a decrease in the same responses with an even higher dose, until the responses are equal to control responses. With MB doses increasing beyond the hormetic zone, the responses decrease even further, until they are below the control responses. At doses spanning its hormetic zone, MB can increase select responses until they are 130-160% of control. For example, low doses of MB produce maximum behavioral and biochemical responses with averages of approximately 140% of control. As MB dose is raised outside the hormetic zone the response decreases below the control response, as exemplified by MB's ability to increase cytochrome oxidase activity at intermediate doses, while decreasing cytochrome oxidase activity at higher doses. It is proposed that MB's autoxidizable chemical property may be responsible for its unique biological action as both a metabolic energy enhancer and antioxidant that is frequently characterized by hormetic dose-response relationships.
authors.affiliation: Departments of Psychology, Pharmacology and Toxicology, University of Texas at Austin, Austin, Texas 78712.
authors.forename: Aleksandra K
authors.initials: AK
authors.lastname: Bruchey
authors.forename: F
authors.initials: F
authors.lastname: Gonzalez-Lima
references.citation: Eur J Pharmacol. 2005 Mar 28;511(2-3):151-8
references.pmid: 15792783
references.citation: J Vet Pharmacol Ther. 1984 Sep;7(3):225-31
references.pmid: 6492250
references.citation: J Clin Anesth. 2007 Jun;19(4):315-21
references.pmid: 17572332
references.citation: Br J Pharmacol. 1997 Sep;122(1):95-8
references.pmid: 9298533
references.citation: FEBS Lett. 1997 Jul 21;412(1):157-60
references.pmid: 9257711
references.citation: Eur Heart J. 1993 Nov;14 Suppl I:22-6
references.pmid: 7507438
references.citation: Biochem Pharmacol. 1991 Jul 15;42(3):499-506
references.pmid: 1650213
references.citation: Toxicol Appl Pharmacol. 2007 Jul 1;222(1):122-8
references.pmid: 17459441
references.citation: Biol Psychiatry. 1986 Aug;21(10):915-20
references.pmid: 3091097
references.citation: Teratology. 1999 Jul;60(1):42-8
references.pmid: 10413340
references.citation: Pharmacol Biochem Behav. 2004 Jan;77(1):175-81
references.pmid: 14724055
references.citation: Basic Life Sci. 1988;49:895-8
references.pmid: 2855011
references.citation: Am J Ther. 2003 Jul-Aug;10(4):289-91
references.pmid: 12845393
references.citation: Pharmacol Res. 1997 Nov;36(5):381-5
references.pmid: 9441729
references.citation: Learn Mem. 2004 Sep-Oct;11(5):633-40
references.pmid: 15466319
references.citation: J Biol Chem. 1966 Mar 10;241(5):1060-6
references.pmid: 5933864
references.citation: Br J Pharmacol. 2007 Nov;152(6):946-51
references.pmid: 17721552
references.citation: Neurosci Lett. 2002 Oct 31;332(2):83-6
references.pmid: 12384216
references.citation: J Pharmacol Toxicol Methods. 2006 Nov-Dec;54(3):273-7
references.pmid: 16488629
references.citation: Am J Physiol Cell Physiol. 2004 Jun;286(6):C1390-8
references.pmid: 14973146
references.citation: Braz J Med Biol Res. 1999 Dec;32(12):1529-32
references.pmid: 10585635
references.citation: Biochemistry. 2007 Jul 31;46(30):8850-60
references.pmid: 17595112
references.citation: Trends Pharmacol Sci. 1995 Feb;16(2):33-6
references.pmid: 7762079
references.citation: FASEB J. 2008 Mar;22(3):703-12
references.pmid: 17928358
references.citation: Neurotox Res. 2006 Jan;9(1):47-57
references.pmid: 16464752
references.citation: J Chemother. 2002 Oct;14(5):431-43
references.pmid: 12462423
references.citation: Shock. 2002 May;17(5):372-6
references.pmid: 12022756
references.citation: Eur J Clin Invest. 2004 Jun;34(6):436-42
references.pmid: 15200496
references.citation: Am J Physiol. 1995 Jul;269(1 Pt 1):L78-84
references.pmid: 7631818
references.citation: Trends Neurosci. 1989 Mar;12(3):94-101
references.pmid: 2469224
references.citation: J Biol Chem. 2005 Mar 4;280(9):7614-23
references.pmid: 15611092
references.citation: Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11213-8
references.pmid: 8855335
references.citation: Clin Chem. 1975 Apr;21(5):1D-432D
references.pmid: 1091375
references.citation: Br J Cancer. 2000 Jan;82(2):291-4
references.pmid: 10646879
references.citation: Clin Neuropharmacol. 1997 Aug;20(4):357-63
references.pmid: 9260734